Amy Sprowles, Humboldt State University - CIRM Stem Cell #SciencePitch Challenge
Congratulations to Amy Sprowles for placing 1st in the CIRM Elevator Pitch Challenge! For more information about about the Elevator Pitch Challenge, see our ...
By: CIRMTV
Read more:
Amy Sprowles, Humboldt State University - CIRM Stem Cell #SciencePitch Challenge - Video
Stem Cell Therapy for Pets - Guiness Before After
Amazing before and after footage of Guiness, an 11 year old dog who received stem cell therapy for his arthritis and got an unexpected side benefit. For more...
By: NewmanVets
Read the original here:
Stem Cell Therapy for Pets - Guiness Before
Stem Cell Therapy for Pets - Sammy Before After
Amazing before and after footage of Sammy, a yellow lab who received stem cell therapy for his arthritic joints. For more information about stem cell therapy...
By: NewmanVets
Follow this link:
Stem Cell Therapy for Pets - Sammy Before
LONDON (ShareCast) - ReNeuron Group (Other OTC: RNUGF - news) has received regulatory approval to begin the first phase of a clinical trial in the UK for the company's ReN009 stem cell therapy treatment for critical limb ischaemia.
Critical limb ischaemia, a condition which leads to blood vessel blockage in limbs such as toes and can lead to amputation, is ReNeuron's second major disease target after stroke in its CTX stem cell line.
The stem cell therapeutics group said ReN009 has the potential to restore sufficient blood flow in the affected lower limb of patients with the condition.
The Phase 1 clinical trial will be undertaken though NHS Tayside at Ninewells Hospital and Medical School in Dundee, Scotland.
ReN009 cells will be administered via straightforward intramuscular injection into the affected lower limb of nine patients with peripheral arterial disease.
ReNeuron was recently awarded a late stage biomedical catalyst grant of 0.4m from the Technology Strategy Board, the UK Government's innovation agency, to be deployed towards the cost of the study.
"These clinical trial approvals for our next major disease target, together with the recently announced biomedical catalyst funding for the Phase I critical limb ischaemia study, represent strong endorsements of the strength of ReNeuron's technologies and its CTX stem cell therapy candidate," said Chief Executive Officer Michael Hunt.
Shares climbed 1.94% to 3.15p at 10:08 Tuesday.
RD
Originally posted here:
ReNeuron Group to begin stem cell treatment of critical limb ischaemia
NEW YORK, March 25, 2013 /PRNewswire/ --Celltex in Houston moved operations to Mexico early this year along with stem cell companies in India and China who have been inquiring about the Mexican market. According to ReHealth, COFEPRIS, which 2 years ago was closed to stem cell treatment has had a complete change of heart when they approached them again just about a month ago. ReHealth's core business is the development of autologous stem cells for diabetes types 1 and 2, COPD, cardiovascular diseases and sports injuries.
The Biopharma Mexico conference, from the 29th-30th October in Mexico City, will usher stem cell and regenerative medicine companies in the US , Europe and Asia into the Mexican market.
Join us and learn how to:
If you offer tools, consumables, reagents, products and services in stem cell development, contact us to find out how you can participate.
Biopharma Mexico will also bring together biotechs developing biologics, particularly bio-comparables and vaccines in the country.
Visit: http://www.terrapinn.com/biopharmamexico
About Terrapinn:
Terrapinn is a business media company. Our products are trade exhibitions, conferences, training solutions and electronic and print publications. More information and a schedule of our events can be found at http://www.terrapinn.com.
Go here to read the rest:
COFEPRIS leniency opens doors to stem cell therapies
Topeka A bill supported by abortion opponents that would require the Kansas University Medical Center to start a center on adult stem cell research was advanced by the House on Tuesday.
State Rep. David Crum, R-Augusta, described the bill as "pro-life," in that adult stem cell research has the "potential to establish cures that improve the quality of life and extend life."
But opponents of Senate Bill 199 said legislators shouldn't mandate KU start a center without any state funding while many of those same legislators also voted to cut funding to the school in the state appropriations bill.
And the opponents said KU did not ask for the bill and that traditionally the startup of a research and treatment center requires a lengthy planning process that brings together school leaders, researchers and the business community before approaching the Legislature.
"We are in uncharted territory," state Rep. Barbara Bollier, R-Mission Hills, said.
"Stem cell research and therapy is incredibly complex," Bollier said. "The doctors and researchers who are involved know what they are doing and they don't need us to set up a specific stem cell treatment center."
Bollier tried to add an amendment to the bill that she said was needed to tighten up legal issues on the research, but her proposal failed 40-74.
State Rep. Susan Concannon, R-Beloit, said it was proper for the Legislature to direct the universities.
"Maybe this would never happen because of the political questions involved," Concannon said. "The stem cell center would possibly never be built if not for the direction of the state."
The bill would require the KU Medical Center to establish the Midwest Stem Cell Therapy Center to advance adult, cord blood and related stem cell therapies.
Read more here:
House advances bill requiring KU Medical Center to establish stem cell research center
The Consumer By Linda Bolido Philippine Daily Inquirer
All the publicity about stem-cell therapy (SCT), including endorsements from some of the countrys most powerful people and brightest stars, has made it seem like a miracle cure, even a cure-all.
From the treatment of life-threatening medical problems to reversing the effects of aging, people are now beginning to look to SCTespecially if they can afford itfor salvation.
But, according to a doctor I know, there are actually only two proven applications for the therapy right now. The rest, at this stage, is really still experimental. People have, of course, volunteered for pioneering procedures, hoping for a cure for whatever ails them.
Education still needed
Thats well and good, as long as they are fully informed and give their unequivocal consent to being experimented on. The problem, however, is some people undergo the therapy without fully understanding it. And there are groups that seem to think that because they have Googled the therapy and read everything on the Net about it, they are capable of doing the procedure.
I mentioned in this column previously that even beauty parlors were offering to do SCT. Although it would be only for cosmetic purposes, the procedure is too new and complex to leave in the hands of beauticians.
Finally, the Department of Health has issued rules and regulations to regulate the SCT practice, a move warmly welcomed by the medical community, particularly the Philippine Medical Association and Philippine Society for Stem Cell Medicine, which expressed concern before that the popularity of SCT would lead to abuse and illegal practice if left unregulated.
Health Secretary Enrique Ona, in published reports, said the guidelines aimed to safeguard the welfare of our patients and the general public by making [sure] safe, effective and ethical stem-cell modalities and practices are within emerging international and global standards considering the very complex nature of this therapy.
Among other things, the rules restrict the use of genetically altered stem cells and tissues of human adults and the umbilical cord, fat-derived human stem cells and live animal stem cells.
DUBLIN, March 25, 2013 /PRNewswire/ --
Research and Markets has announced the addition of the "Complete 2012-13 Induced Pluripotent Stem Cell Industry Report" report to their offering.
(Logo: http://photos.prnewswire.com/prnh/20130307/600769 )
Stem cell research and experimentation has been in process for well over five decades. Stem cells have the unique characteristics whereby they are able to divide and replicate repeatedly in addition to their being unspecialized with the ability to differentiate into specialized cell types. The possibilities that arise with the perfecting of cell replication has caused this area of exploration to remain on the forefront of scientific research, with ongoing hope that cures and treatment of diseases as well as reparative cell therapy, tissue regeneration and pharmacological testing on cell-specific tissue will one day become viable options within the medical community.
Traditionally, scientists have worked with both embryonic and adult stem cells. While the appeal of embryonic cells has been their ability to differentiate into any type of cell, there has been significant ethical, moral and spiritual controversy surrounding the use of embryonic cells for research. Although adult stem cells can differentiate slightly, they are typically limited to differentiation within their original tissue type, creating narrow options for their use.
Perhaps the most distinctive feature of this report are the breakthrough findings discovered as a result of surveying 293 researchers that identify as having induced pluripotent stem cells as their core research focus. Of the 293 respondents, 181 were U.S. based and 112 were international. These key survey findings reveal iPSC researcher wants and needs, technical preferences, and key factors influencing buying decisions. These vital findings can be used to direct the product development and product positioning decisions. Remember, to benefit from this lucrative product market, you need to anticipate and serve the needs of your clients, or your competitors will.
Key Findings Include:
- Charts, Timelines, Metrics and Financials for the iPSC Research Product Market
- Trends for iPSC Grants, Publications, Patents, and More
- 5-Year Market Projection Data for 2012-2017
See the article here:
Complete 2012-13 Induced Pluripotent Stem Cell Industry Report
"STEM cell therapy is now in Davao City," announced by Dr. Luz P. Acosta, founding member of the Philippine Society for Stem Cell Medicine.
The stem cell treatment that is made available in the city is the internationally-recognized procedure approved by the Department of Health (DOH) and the Food and Drug Administration (FDA).
Acosta explained that the process starts with taking a collection of platelet-rich plasma (blood) and autologous adipose tissue (fat) from the patient.
From these, the stem cells are then isolated and activated through the use of machines technologically enhanced to perform such tasks.
She said the stem cells are then ready to be administered to the patient through local injections as needed. The whole process, she added, is done in approximately two to three hours, under local anesthesia. No hospital admission is required.
The body will not incur any adverse reactions, according to the medical expert, since only the patient's own cells are being used in the process, contrary to that of the controversial procedures which use fetal or animal stem cells that each pose ethical and religious issues or genetic and ancestral issues, respectively.
The revolutionary stem cell treatment, according to Acosta, has had documented success in the treatment of diabetes, autism, Alzeihmer's disease, liver cirrhosis, multiple sclerosis, erectile dysfunction, kidney diseases, and lung diseases.
"There is no longer a need for Dabawenyos to go out of the country or fly to Manila to receive treatment for various diseases which had previously rendered patients desperate and hopeless." Acosta said.
Published in the Sun.Star Davao newspaper on March 27, 2013.
Read more from the original source:
Stem cell treatment now available in Davao City
WALTHAM, Mass.--(BUSINESS WIRE)--
ViaCord, PerkinElmers family cord blood and tissue preservation business, announced today the release of its 250th umbilical cord blood stem cell unit for use in medical treatments and clinical trials. For nearly 20 years, ViaCord has released life-saving stem cells for disease therapies using a proven method of processing and cryopreserving cord blood. To date, ViaCord has released more units for use in medical treatments and clinical trialsthan any other family bank.
Reaching this milestone is a testament to our dedication to improving the quality of life for families, said Morey Kraus, Chief Scientific Officer, ViaCord. The benefits of cord blood banking are constantly evolving as research, some of which ViaCord has been instrumental in supporting, continues to expand the number of diseases treated. We are excited to continue to assist families who have chosen to bank their newborns stem cells.
Cord blood stem cells have been used in the treatment of nearly 80 diseases, and more than 30,000 treatments have been conducted worldwide using cord blood stem cells. ViaCord has released stem cells for the treatment of diseases ranging from acute lymphoblastic leukemia, thalassemia major and sickle cell disease. ViaCords 250th unit was used to treat a patient currently enrolled in the Duke Translational Medicine Institutes Cerebral Palsy Autologous Cord Blood clinical trial conducted at Duke University Medical Center. In this clinical trial, researchers are investigating the potential benefits of autologous reinfusion of cord blood stem cells for children with cerebral palsy.
ViaCord has preserved the umbilical cord stem cells of more than 300,000 newborns. ViaCords family cord blood and cord tissue services currently offer expectant families the opportunity to bank their baby's umbilical cord blood and tissue for potential medical use by the child or a related family member. Through its Sibling Connection Program, ViaCord also provides the opportunity for expectant parents, who have an eligible child in need of a transplant, to receive cord blood and cord tissue stem collection, processing and five years of storage, at no cost.
Please visit http://www.viacord.com for more information.
About PerkinElmer, Inc. PerkinElmer, Inc. is a global leader focused on improving the health and safety of people and the environment. The company reported revenue of approximately $2.1 billion in 2012, has about 7,500 employees serving customers in more than 150 countries, and is a component of the S&P 500 Index. Additional information is available through 1-877-PKI-NYSE, or at http://www.perkinelmer.com.
Excerpt from:
ViaCord Releases 250th Cord Blood Stem Cell Unit